- Published on
Claude Science is Anthropic’s newest flagship product
- Authors
- Name
- DeepHorus
Anthropic has launched Claude Science, a flagship product designed to support scientific research, mirroring the capabilities of its Claude Code for software engineering. Announced Tuesday at an event for pharmaceutical executives, biotech founders, and researchers, the tool can autonomously execute complex tasks from high-level instructions and specializes in computational biology and drug development. Claude Science is now available to all paid Claude subscribers, and Anthropic also revealed plans to use the product for its own research into rare and neglected diseases.
This is not Anthropic’s first AI-for-science initiative—in October, it released plug-ins under “Claude for Life Sciences” that integrated scientific software and databases. However, Claude Science is a full-featured standalone product, elevated to the same tier as Claude Code and Claude Cowork. Eric Kauderer-Abrams, Anthropic’s head of life sciences, stated, “It represents how important this is to our mission… Our mission is to develop AI that serves humanity’s long-term well-being, and we believe that by far the greatest opportunity to do that is in the life sciences.”
For a decade, Google DeepMind led AI for science, with CEO Demis Hassabis and John Jumper winning the Nobel Prize in Chemistry for AlphaFold. DeepMind also contributed to meteorology and materials science, but recent advances in large language models have left it trailing, especially in coding—the most lucrative AI use case. Anthropic is positioned to take up the mantle, as CEO Dario Amodei holds a PhD in science, unlike OpenAI’s Sam Altman. Many scientists already use Claude tools, and earlier this month, Jumper announced he is leaving DeepMind for Anthropic.
Claude Science builds on scientists’ existing workflows without replacing Claude Code or Cowork. It not only writes code but also helps run it on powerful computer clusters, which many scientists need but find challenging to manage. The tool prioritizes reproducibility, allowing users to trace results back to their source for verification. Harvard physicist Matthew Schwartz estimated, based on his work with Claude Code, that Anthropic’s Opus 4.5 model matches the capability of a second-year graduate student in executing scientific projects.
The launch signals a strategic bet that AI’s greatest impact lies in life sciences, aligning with Anthropic’s mission. By offering a dedicated product, Anthropic hopes to attract researchers who need autonomous, reliable assistance for complex computational tasks. The move also intensifies competition with DeepMind, which now faces a talent drain and product gap.
Looking ahead, Claude Science could accelerate drug discovery and other scientific breakthroughs. Anthropic’s own research into rare diseases will serve as a proof of concept. As AI agents become more capable, the line between human and machine contribution in science may blur, raising questions about collaboration and attribution. For now, Anthropic is betting that dedicated tools for science will drive its growth and impact.
